Ignite Creation Date:
2025-12-25 @ 3:38 AM
Ignite Modification Date:
2026-04-01 @ 2:56 AM
Study NCT ID:
NCT04830202
Status:
AVAILABLE
Last Update Posted:
2025-10-03
First Post:
2021-03-31
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Expanded Access to Telisotuzumab Vedotin
Sponsor:
AbbVie
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
None
Start Date Type:
None
Primary Completion Date:
None
Primary Completion Date Type:
None
Completion Date:
None
Completion Date Type:
None
First Submit Date:
2021-03-31
First Submit QC Date:
None
Study First Post Date:
2021-04-05
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-09-30
Last Update Post Date:
2025-10-03
Last Update Post Date Type:
ESTIMATED